| Revenue growth | 17.3% YoY for FY26. |
|---|---|
| Margins | Consolidated EBITDA margin improved to 22.8% from 20.4%. |
| Demand visibility | Strong hospital occupancy (68-90% in key units). |
| Management confidence | High; tracking toward 25% margin target by FY28. |
Growth
FY26 Consolidated Revenue up 17.3% to ₹9,128 Cr; Hospital revenue grew 19.1%; PAT increased 31.5% to ₹1,064 Cr.
Outlook
Guided 15%+ revenue growth for FY27; 150 bps margin expansion; ₹900 Cr annual capex for 1,800+ bed expansion.
Risks
International business volatility; regulatory drug price caps in Oncology (Punjab/North); intense competition in Bangalore and NCR markets.
Earnings Call filed with NSE, NSE: FORTIS. Summary written with AI assistance from the document.
Fortis Healthcare Ltd: key numbers
- Share price
- ₹774.90
- Market cap
- ₹58,502 Cr
- Revenue (annual)
- ₹9,128 Cr
- Net profit (annual)
- ₹1,042 Cr
- P/E (TTM)
- 55.8×Sector 53.1×
- Promoter holding
- 31.17%+0.00% QoQ
- FII holding
- 25.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fortis Healthcare Ltd
All →Fortis Healthcare Legal & Regulatory
Northern TK Venture Pte Ltd, Fortis Healthcare's promoter, has appealed a Tokyo District Court judgment to the Tokyo High Court. The litigation concerns losses related to delayed tender offer approvals.
Fortis Healthcare Partnership
Fortis Hospotel signed definitive agreements with SLJ Society to provide healthcare services at their 400+ bed hospital. Fortis will provide a ₹567 Crore loan.
- Value
- ₹567.0 Cr
- From
- Seth Sunder Lal Jain Charitable Eye Hospital (SLJ Society)
- hospital beds
- 400.0 beds
Fortis Healthcare Legal & Regulatory
Tokyo District Court dismissed all NTK claims against Daiichi Sankyo; NTK must bear litigation costs. NTK is reviewing the judgment and evaluating appeal options.
Fortis Healthcare Earnings Call Transcript: Key Takeaways
Management conference call discussing a Delhi High Court order regarding a forensic audit. Operating plans, including capex, bed expansion, and M&A, remain unaffected and fully funded by internal accruals.
Fortis Healthcare Legal & Regulatory
The Delhi High Court has ordered a forensic audit concerning shareholding changes and control of Fortis Healthcare's erstwhile promoters. The company faces no liability or penalty.
Fortis Healthcare Other Announcement
Fortis Healthcare Limited received a voluntary ESG rating for FY 2025-26 from Crisil ESG Ratings & Analytics Ltd, with a rating category of 'Strong'.